Thalidomide for necrobiotic xanthogranuloma
- PMID: 34856016
- DOI: 10.1111/ced.15047
Thalidomide for necrobiotic xanthogranuloma
Comment in
-
Monoclonal gammopathy of cutaneous significance.Clin Exp Dermatol. 2022 Apr;47(4):778. doi: 10.1111/ced.15062. Epub 2021 Dec 30. Clin Exp Dermatol. 2022. PMID: 34905231 No abstract available.
Comment on
-
The role of thalidomide in dermatology.Clin Exp Dermatol. 2022 Apr;47(4):667-674. doi: 10.1111/ced.15019. Epub 2021 Dec 19. Clin Exp Dermatol. 2022. PMID: 34779533 Review.
References
-
- Hussain K, Patel P, Roberts N. The role of thalidomide in dermatology. Clin Exp Dermatol 2021. https://doi.org/10.1111/ced.15019. Online ahead of print.
-
- Nelson CA, Zhong CS, Hashemi DA et al. A multicenter cross-sectional study and systematic review of necrobiotic xanthogranuloma with proposed diagnostic criteria. JAMA Dermatol 2020; 156: 270-9.
-
- Hauser C, Schifferli J, Saurat JH. Complement consumption in a patient with necrobiotic xanthogranuloma and paraproteinemia. J Am Acad Dermatol 1991; 24: 908-11.
-
- Efebera Y, Blanchard E, Allam C et al. Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk 2011; 11: 298-302.
-
- Koch D, Lucas G, Durrington P, Lear JT. Ulcerating necrobiotic xanthogranulomata and paraproteinaemia treated with thalidomide. Br J Dermatol 2008; 159: 16-17.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources